Drug
Zanidatamab
Zanidatamab: highest development phase Phase 3, developed by BeiGene, Jazz Pharmaceuticals, Zymeworks. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene, Jazz Pharmaceuticals, Zymeworks
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zanidatamab NCT06282575 | Phase 3 | Biliary Tract Cancer |
| Zanidatamab NCT05152147 | Phase 3 | Gastric Neoplasms |
| Zanidatamab NCT05035836 | Phase 2 | Breast Cancer |
| Zanidatamab NCT06695845 | Phase 2 | Breast Cancer |
| Zanidatamab NCT05027139 | Phase 1/2 | HER2-expressing Cancers |
| Zanidatamab NCT04276493 | Phase 1/2 | Breast Cancer |
Latest
Follow Zanidatamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.